Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shinpoong Pharmaceutical Co's inventories, raw materials & components for the quarter that ended in Jun. 2026 was ₩24,566 Mil.
Shinpoong Pharmaceutical Co's quarterly raw materials
declined
from Dec. 2025 (₩23,002 Mil) to Mar. 2026 (₩22,623 Mil) but then
increased
from Mar. 2026 (₩22,623 Mil) to Jun. 2026 (₩24,566 Mil).
Shinpoong Pharmaceutical Co's annual raw materials
increased
from Dec. 2023 (₩16,468 Mil) to Dec. 2024 (₩21,124 Mil) and
increased
from Dec. 2024 (₩21,124 Mil) to Dec. 2025 (₩23,002 Mil).
Shinpoong Pharmaceutical Co Inventories, Raw Materials & Components Historical Data
* Premium members only.
The historical data trend for Shinpoong Pharmaceutical Co's Inventories, Raw Materials & Components can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shinpoong Pharmaceutical Co Inventories, Raw Materials & Components Chart
What does a Inventories, Raw Materials & Components of ₩24,566 Mil mean?
Shinpoong Pharmaceutical Co (XKRX:019170) has a Inventories, Raw Materials & Components of ₩24,566 Mil as of Jun. 2026. Raw materials are the components a company uses for its main products. View historical data on Shinpoong Pharmaceutical Co and its competitors.
Is Shinpoong Pharmaceutical Co's Inventories, Raw Materials & Components too high?
Shinpoong Pharmaceutical Co's current Inventories, Raw Materials & Components is ₩24,566 Mil. Overall, Shinpoong Pharmaceutical Co has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shinpoong Pharmaceutical Co's Inventories, Raw Materials & Components compare to ZTS?
Shinpoong Pharmaceutical Co's Inventories, Raw Materials & Components of ₩24,566 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Drug Manufacturers company?
A good Inventories, Raw Materials & Components depends on the Drug Manufacturers industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Shinpoong Pharmaceutical Co and its competitors. Shinpoong Pharmaceutical Co's current Inventories, Raw Materials & Components is ₩24,566 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shinpoong Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shinpoong Pharmaceutical Co (XKRX:019170) is currently considered Modestly Undervalued. The stock's GF Value™ is ₩11,211.69, compared to a current price of ₩9,970.00 — trading 11.1% below its estimated fair value. The current Inventories, Raw Materials & Components is ₩24,566 Mil. Shinpoong Pharmaceutical Co's overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Shinpoong Pharmaceutical Co (XKRX:019170), the current Inventories, Raw Materials & Components is ₩24,566 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shinpoong Pharmaceutical Co (XKRX:019170) Overvalued in 2026?
Based on GuruFocus' analysis, Shinpoong Pharmaceutical Co stock appears to be undervalued.
The current stock price of ₩9,970.00 is trading 11.1% below its estimated GF Value™ of ₩11,211.69.
GuruFocus considers Shinpoong Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for XKRX:019170:
Inventories, Raw Materials & Components: ₩24,566 Mil
GF Value™: ₩11,211.69 vs. price of ₩9,970.00 (11.1% below fair value)
No single metric tells the full story. See the XKRX:019170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shinpoong Pharmaceutical Co Ltd specializes in manufacturing remedy drugs and also active pharmaceutical ingredients and finished products. Its products include Newsicam, Caravenal, Roxagen, Clamoxin duo, Ceroxim, and Clocin. The firm's production facilities are located at Gyeonggi-do and Cheongwon-gun.
65GF Score
Get the complete analysis for XKRX:019170
Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:019170 has been successfully added to your 
